Pediatrix Medical Group, Inc. - 10-Q Summary (Period Ended June 30, 2008)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2008 for Pediatrix Medical Group, Inc. (PMG), a provider of neonatal, pediatric, and maternal-fetal medical services. The reporting period includes the results of five physician group practices acquired during the first half of 2008. Notably, the Company completed the sale of its newborn metabolic screening laboratory business on February 29, 2008, which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2008 | Six Months Ended June 30, 2007 |
|---|---|---|
| Net Patient Service Revenue | $503.3 million | $434.2 million |
| Net Income | $92.8 million | $61.9 million |
| Income from Continuing Operations | $70.3 million | $60.7 million |
| Diluted EPS (Continuing Ops) | $1.46 | $1.21 |
| Operating Margin | 22.7% | 21.8% |
| Cash and Cash Equivalents | $14.2 million | $136.6 million (end of period 2007) |
| Working Capital | $24.6 million | $99.2 million (Dec 31, 2007) |
| Debt (Line of Credit) | $57.5 million | $0 (Dec 31, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Net patient service revenue increased 15.9% ($69.1 million) year-over-year. Approximately 60.2% of this increase was attributable to acquisitions, while same-unit revenue grew 6.5% due to pricing improvements and volume growth in maternal-fetal and cardiology services.
- Discontinued Operations: Net income includes a significant one-time gain of $22.0 million (after-tax) from the sale of the newborn metabolic screening laboratory business. Excluding this, income from continuing operations grew 15.8%.
- Share Repurchases: The Company completed two $100 million share repurchase programs in the first half of 2008, purchasing approximately 3.4 million shares. This significantly reduced cash reserves and weighted average shares outstanding.
- Expense Management: General and administrative expenses decreased 2.5% year-over-year, primarily due to the absence of $3.3 million in stock option review professional fees and $3.4 million in 409A tax obligations incurred in the prior year.
- Liquidity: Cash and cash equivalents decreased by $88.6 million, driven by stock repurchases ($200 million) and acquisition payments ($47.7 million), partially offset by operating cash flow and the sale of the laboratory business.
Guidance, Outlook, and Risks
- Outlook: Management anticipates an effective tax rate of approximately 39.25% for the full year 2008. The Company expects funds from operations, current cash, and its line of credit to be sufficient for working capital and acquisitions for the next 12 months.
- Legal Proceedings: The Company is cooperating with a formal SEC investigation and a U.S. Attorney's office inquiry regarding historical stock option granting practices. A shareholder derivative lawsuit regarding these practices was settled in April 2008 for $1.5 million in legal fees (covered by insurance).
- Regulatory Compliance: The Company is subject to a five-year Corporate Integrity Agreement with the Office of Inspector General (OIG) following a 2006 settlement regarding billing practices. Failure to comply could result in exclusion from federal healthcare programs.
- Debt Covenants: The Company has a $225 million line of credit maturing in July 2009. It currently has $57.5 million outstanding and is in compliance with financial covenants.
Investor Verification Checklist
- Verify the sustainability of revenue growth excluding the impact of recent acquisitions.
- Monitor the status and potential financial impact of the ongoing SEC and U.S. Attorney's office investigations into stock option practices.
- Assess the adequacy of the $22.0 million liability for unrecognized tax benefits and potential future adjustments.
- Review the Company's ability to refinance its $225 million line of credit prior to its July 2009 maturity.
- Confirm compliance with the Corporate Integrity Agreement obligations to avoid exclusion from federal healthcare programs.